EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark
Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.